Robert M Rifkin, MD, FACP, gave an update on the basics, education, and reimbursement of biosimilars, stating that “this will be a huge year” for the the copycat biologics in the United States.
A recent study compared the costs and toxicities of proton radiation, stereotactic body radiotherapy, and intensity-modulated radiotherapy for younger patients with prostate cancer.
Younger patients who received certain chemotherapies for solid tumors or leukemia may not have T-cells capable of becoming effective CAR T-cells.
A recent study investigated whether risk-standardized mortality rate is an effective predictor of long-term survival in hospitalized patients with heart failure.
Results of a large study supported by the National Cancer Institute found that patients who survived testicular cancer are at a higher risk of developing heart disease.
Treatment with a BTK inhibitor has been shown to yield good depth and duration of response in patients with chronic lymphocytic leukemia, regardless of TP53 status.
Long-term data show that a CAR-T therapy induces significant clinical benefit without added adverse events among patients with refractory aggressive non-Hodgkin lymphoma.
CAR T-cell therapy may compliment HSCT for improving survival in ALL without increasing the risk of severe graft-versus-host disease, according to research presented at the 2018 BMT Tandem Meetings.
A study to be presented at the BMT Tandem Meetings found no difference in OS for patients aged 55-64 years compared with those aged 65 years and older with non-Hodgkin lymphoma who underwent alloHCT.
A recent study found that a biosimilar provides improved outcomes without increased risk of toxicity for patients with DLBCL and treatment-induced neutropenia.